J
Jack H. Simon
Researcher at Anschutz Medical Campus
Publications - 84
Citations - 10079
Jack H. Simon is an academic researcher from Anschutz Medical Campus. The author has contributed to research in topics: Multiple sclerosis & Interferon beta-1a. The author has an hindex of 42, co-authored 84 publications receiving 9847 citations. Previous affiliations of Jack H. Simon include University of Colorado Denver & University of Rochester Medical Center.
Papers
More filters
Journal ArticleDOI
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
Lawrence Jacobs,Diane Cookfair,Richard A. Rudick,Robert M. Herndon,John R. Richert,Andres M. Salazar,J. S. Fischer,Donald E. Goodkin,Carl V. Granger,Jack H. Simon,John J. Alam,David M. Bartoszak,Dennis Bourdette,Jonathan Braiman,Carol M. Brownscheidle,Michael E. Coats,Stanley Cohan,David S. Dougherty,R. P. Kinkel,Michele Mass,Frederick Munschauer,Roger L. Priore,Patrick M. Pullicino,Barbara J. Scherokman,Bianca Weinstock-Guttman,Ruth H. Whitham +25 more
TL;DR: Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.
Journal ArticleDOI
Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
TL;DR: The brain parenchymal fraction is a marker for destructive pathologic processes ongoing in relapsing MS patients, and appears useful in demonstrating treatment effects in controlled clinical trials.
Journal ArticleDOI
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
Jeffrey A. Cohen,Gary Cutter,J. S. Fischer,Andrew D. Goodman,Fedor Heidenreich,Mariska F. Kooijmans,Alfred Sandrock,Richard A. Rudick,Jack H. Simon,N. A. Simonian,E. C. Tsao,John N. Whitaker +11 more
TL;DR: IFN&bgr;-1a demonstrated benefit on MSFC progression, relapses, quality of life, and MRI activity in SPMS.
Journal ArticleDOI
Eight-year follow-up study of brain atrophy in patients with MS
Elizabeth Fisher,Richard A. Rudick,Jack H. Simon,Gary Cutter,Monika Baier,Jar-Chi Lee,David Miller,Bianca Weinstock-Guttman,Michele Mass,D. S. Dougherty,N. A. Simonian +10 more
TL;DR: Atrophy rate during the original trial was the most significant MRI predictor of disability status at follow-up and the relation between atrophy progression and subsequent neurologic disability status suggests thatatrophy progression during RRMS is clinically relevant, Therefore, atrophy progress may be a useful marker for disease progression in clinical trials.
Journal ArticleDOI
A longitudinal study of brain atrophy in relapsing multiple sclerosis
Jack H. Simon,Lawrence Jacobs,M. Campion,Richard A. Rudick,Diane Cookfair,Robert M. Herndon,John R. Richert,Andres M. Salazar,J. S. Fischer,Donald E. Goodkin,N. A. Simonian,M. Lajaunie,D. E. Miller,K. E. Wende,A. Martens-Davidson,R. P. Kinkel,Frederick Munschauer,Carol M. Brownscheidle +17 more
TL;DR: In patients with relapsing MS and only mild to moderate disability, significant cerebral atrophy is already developing that can be measured over periods of only 1 to 2 years.